Equities research analysts expect that PetMed Express, Inc. (NASDAQ:PETS) will post earnings of $0.29 per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for PetMed Express’ earnings. The highest EPS estimate is $0.31 and the lowest is $0.28. PetMed Express posted earnings per share of $0.24 in the same quarter last year, which suggests a positive year-over-year growth rate of 20.8%. The business is expected to announce its next earnings report on Monday, October 23rd.

According to Zacks, analysts expect that PetMed Express will report full-year earnings of $1.41 per share for the current year, with EPS estimates ranging from $1.40 to $1.42. For the next year, analysts anticipate that the business will post earnings of $1.51 per share, with EPS estimates ranging from $1.49 to $1.53. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover PetMed Express.

PetMed Express (NASDAQ:PETS) last released its earnings results on Monday, July 24th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.07. PetMed Express had a return on equity of 28.67% and a net margin of 10.34%. The firm had revenue of $79.66 million for the quarter, compared to the consensus estimate of $77.32 million. During the same period in the prior year, the firm earned $0.32 EPS. The firm’s revenue was up 9.9% on a year-over-year basis.

Several brokerages have recently weighed in on PETS. Northcoast Research upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 target price for the company in a research note on Monday, July 24th. Noble Financial restated a “hold” rating on shares of PetMed Express in a research note on Wednesday, July 26th. Craig Hallum restated a “hold” rating and issued a $40.00 target price (down from $43.00) on shares of PetMed Express in a research note on Monday, August 21st. They noted that the move was a valuation call. BidaskClub downgraded shares of PetMed Express from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 22nd. Finally, Sidoti upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Thursday, August 24th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $44.75.

PetMed Express (NASDAQ:PETS) traded down 1.45% during trading on Friday, hitting $35.33. The company had a trading volume of 736,497 shares. The stock has a market capitalization of $716.92 million, a price-to-earnings ratio of 27.18 and a beta of 1.03. The firm’s 50 day moving average is $40.97 and its 200-day moving average is $33.60. PetMed Express has a 52-week low of $18.90 and a 52-week high of $50.90.

In other PetMed Express news, CFO Bruce S. Rosenbloom sold 6,833 shares of the stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.18, for a total transaction of $342,879.94. Following the transaction, the chief financial officer now directly owns 18,534 shares in the company, valued at approximately $930,036.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronald J. Korn sold 5,000 shares of the stock in a transaction on Friday, July 28th. The shares were sold at an average price of $48.18, for a total transaction of $240,900.00. Following the transaction, the director now owns 67,333 shares in the company, valued at $3,244,103.94. The disclosure for this sale can be found here. Insiders have sold a total of 19,333 shares of company stock worth $949,730 over the last quarter. 4.00% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Pinebridge Investments L.P. boosted its stake in PetMed Express by 1.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after acquiring an additional 27 shares during the last quarter. Arizona State Retirement System boosted its stake in PetMed Express by 0.9% during the 1st quarter. Arizona State Retirement System now owns 10,667 shares of the company’s stock valued at $215,000 after acquiring an additional 100 shares during the last quarter. Texas Permanent School Fund boosted its stake in PetMed Express by 0.8% during the 2nd quarter. Texas Permanent School Fund now owns 14,986 shares of the company’s stock valued at $608,000 after acquiring an additional 125 shares during the last quarter. Advisor Group Inc. boosted its stake in PetMed Express by 0.7% during the 2nd quarter. Advisor Group Inc. now owns 24,844 shares of the company’s stock valued at $1,009,000 after acquiring an additional 179 shares during the last quarter. Finally, QS Investors LLC boosted its stake in PetMed Express by 4.0% during the 2nd quarter. QS Investors LLC now owns 9,324 shares of the company’s stock valued at $379,000 after acquiring an additional 356 shares during the last quarter. Hedge funds and other institutional investors own 78.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/24/0-29-eps-expected-for-petmed-express-inc-pets-this-quarter.html.

PetMed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Get a free copy of the Zacks research report on PetMed Express (PETS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.